Comparison
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739 vs 17q11 2 Microduplication Syndrome C3495679
Clinical comparison between 3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome and 17q11 2 Microduplication Syndrome for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739
A severe mitochondrial disorder affecting the brain, hearing, and energy metabolism. It causes progressive neurological decline, hearing loss, and metabolic problems. Management requires intensive supportive care.
17q11 2 Microduplication Syndrome C3495679
A genetic disorder caused by duplication of a segment on chromosome 17. Individuals may have developmental delays, behavioral concerns, and physical features. Treatment focuses on early intervention.
6 comparison axes
Onset
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739
0-5
17q11 2 Microduplication Syndrome C3495679
0-null
Onset patterns differ
Severity
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739
severe
17q11 2 Microduplication Syndrome C3495679
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739
Chronic
17q11 2 Microduplication Syndrome C3495679
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739
No
17q11 2 Microduplication Syndrome C3495679
No
Different transmission
Body System
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739
metabolic
17q11 2 Microduplication Syndrome C3495679
congenital
Same/different system
Category
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739
metabolic
17q11 2 Microduplication Syndrome C3495679
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-with-deafness-encephalopathy-and-leigh-like-syndrome-C4040739 and 17q11-2-microduplication-syndrome-C3495679 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739 | 17q11 2 Microduplication Syndrome C3495679 | Discriminating power |
|---|---|---|---|
| Neurologic course | Progressive encephalopathy and Leigh-like neurologic decline may occur. | Developmental delay may occur without an established progressive metabolic encephalopathy. | High |
| Hearing | Hearing loss is a recognized feature. | Hearing loss is not established as a defining feature. | Moderate |
| Development and behavior | Neurologic impairment may dominate the presentation. | Developmental delay, behavioral concerns, and physical features may be present. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739 when
Early progressive neurologic decline with hearing loss
This pattern aligns with the described mitochondrial disorder.
Moderate
Suspected metabolic or mitochondrial disease
The left condition is categorized as a severe metabolic disorder.
Moderate
Leigh-like brain involvement is clinically suspected
Leigh-like features are part of the left condition’s description.
Moderate
Choose 17q11 2 Microduplication Syndrome C3495679 when
Developmental delay with behavioral concerns
These features fit the described chromosomal duplication syndrome.
Moderate
Congenital genetic syndrome is suspected
The right condition is a congenital chromosomal disorder.
Moderate
No established progressive metabolic encephalopathy
Absence of that course makes the right condition more plausible, but does not confirm it.
Low
How key tests differ
| Test | 3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739 | 17q11 2 Microduplication Syndrome C3495679 | Interpretation |
|---|---|---|---|
| Metabolic evaluation | Abnormal organic-acid findings may support the diagnosis; exact cutoffs are not established here. | No specific metabolic abnormality is established. | An abnormal result is not itself a diagnosis and requires clinician review. |
| Chromosomal microarray | A 17q11.2 duplication is not the defining finding. | Duplication of the 17q11.2 segment supports the diagnosis. | Genetic confirmation should be interpreted with clinical findings. |
| Hearing and neurologic assessment | Hearing loss and progressive neurologic findings may be documented. | Developmental or behavioral findings may be documented. | Assessments characterize impact but do not alone distinguish the conditions. |
Prognosis comparison
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739
- Outcome
- Potentially severe progressive neurologic and metabolic course; exact survival is not established.
- Factors
- Neurologic progression, hearing loss, and metabolic complications may influence outlook.
17q11 2 Microduplication Syndrome C3495679
- Outcome
- Generally described as moderate, but individual outcomes vary and are not fully established.
- Factors
- Developmental, behavioral, and physical features may influence support needs.
Time frame: Both are chronic; left onset is described in early childhood, while right onset timing is not fully specified.
Prognosis should be individualized by clinicians; no mortality figures are established here.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic deterioration | Progressive decline may occur and can be severe. Progressive metabolic encephalopathy is not established. Course varies and requires specialist monitoring. |
| Hearing impairment | Hearing loss is a recognized concern. Hearing impairment is not established from the supplied description. Audiology referral depends on clinical findings. |
| Developmental and behavioral needs | Neurologic disease may substantially affect development. Developmental delay and behavioral concerns may require support. Needs should be individualized; exact outcomes are not established. |
Patient education highlights
- HighDifferent causes
One condition is a severe mitochondrial metabolic disorder; the other is a chromosomal duplication syndrome.
- HighSpecialist care
Diagnosis and management require qualified clinicians; supportive care or early intervention may be needed.
- MediumNot contagious
Neither condition is described as communicable.